Origin

China

Enoxaparin sodium

Enoxaparin is a low molecular weight heparin.It is used to prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a subcutaneous injection (by a health care provider or the patient). Its use is evolving in acute coronary syndromes (ACS).

Enoxaparin is is derived from the intestinal mucosa of pigs.

Indications

In the UK and Australia, enoxaparin is approved for six indications:

• The prophylaxis of thromboembolism disorders of venous origin, in particular those which may be associated with orthopaedic surgery. There is limited evidence supporting the use of enoxaparin in orthoapedic patients, although evidence is reasonable for colorectal patients
• The prophylaxis of venous thromboembolism (VTE) in medical patients bedridden due to acute illness.
• The treatment of venous thromboembolism disease (VTED) presenting with deep vein thrombosis (DVT), pulmonary embolism (PE) or both.
• The treatment of unstable angina (UA) and non-Q-wave myocardial infarction (NQMI), administered concurrently with aspirin.
• The prevention of thrombus formation in the extracorporeal circulation during haemodialysis.
• The prevention of thrombus formation during episodes of lone Atrial Fibrillation, administered concurrently with aspirin (in the absence of long term blood thinning treatment with warfarin).

In the United States, enoxaparin is FDA approved for eight indications:

• Prophylaxis of DVT in medically ill patient,
• Total hip & knee replacement,
• Extended hip-replacement,
• Abdominal surgery.
• Treatment of DVT with or without PE inpatient and
• Treatment of DVT inpatient, with ACS, including STEMI.

Specification

0.2ml/20mg

0.4ml/40mg

0.6ml/60mg

0.8ml/80mg

1.0ml/100mg